1. Home
  2. LFMD vs PLX Comparison

LFMD vs PLX Comparison

Compare LFMD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LifeMD Inc.

LFMD

LifeMD Inc.

HOLD

Current Price

$4.06

Market Cap

190.9M

Sector

Health Care

ML Signal

HOLD

Logo Protalix BioTherapeutics Inc. (DE)

PLX

Protalix BioTherapeutics Inc. (DE)

HOLD

Current Price

$2.32

Market Cap

174.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFMD
PLX
Founded
1994
1993
Country
United States
United States
Employees
384
N/A
Industry
Medical/Nursing Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.9M
174.0M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
LFMD
PLX
Price
$4.06
$2.32
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
1
Target Price
$9.14
$12.00
AVG Volume (30 Days)
910.9K
827.6K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$52,744,000.00
Revenue This Year
$17.52
$36.81
Revenue Next Year
$18.73
$1.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.60
$1.34
52 Week High
$15.34
$3.19

Technical Indicators

Market Signals
Indicator
LFMD
PLX
Relative Strength Index (RSI) 61.04 47.94
Support Level $3.39 $2.03
Resistance Level $4.19 $2.45
Average True Range (ATR) 0.29 0.08
MACD 0.03 0.03
Stochastic Oscillator 77.94 81.16

Price Performance

Historical Comparison
LFMD
PLX

About LFMD LifeMD Inc.

LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.

About PLX Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Share on Social Networks: